Pharmacological inhibition of Cxcr3 in murine malignant glioma (GL261) model showed antitumor progression effect (Liu et al., 2011), suggesting the connection between CXCR3 and glioma progression and CXCR3 could be a potential therapeutic target for glioma. This evidence concerns the gene CXCR3 and glioma.